SYS-CON MEDIA Authors: Elizabeth White, Yeshim Deniz, Roger Strukhoff, Jason Bloomberg, Pat Romanski

News Feed Item

Announcing a New Era in Alzheimer's

MONTE CARLO, Monaco, October 30, 2012 /PRNewswire/ --

The time for Tau is now  as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's

TauRx Therapeutics Ltd announced today the initiation of two global Phase 3 clinical trials in mild to moderate Alzheimer's disease. These landmark studies could provide the first definitive data on a Tau-based approach to disease-modifying and preventative treatment of Alzheimer's for at least the next 5-7 years, said Professor Claude Wischik, Chairman of TauRx and Professor of Old Age Psychiatry at the University of Aberdeen, in a press conference at the 5th Clinical Trials Conference on Alzheimer's Disease (CTAD) in Monte Carlo, Monaco today.

The studies culminate three decades of research by Professor Wischik and colleagues, including the original discovery of the Tau protein as the main constituent of the Tangle pathology of Alzheimer's disease ['Tau tangles'], the development of the first Tau Aggregation Inhibitor (TAI), and results from an earlier Phase 2 clinical trial involving more than 300 patients that showed a 90% reduction in the rate of disease progression over two years.[1]

"These Phase 3 studies are bringing us closer to finding an effective treatment that can actually arrest the progression of the disease," said Professor Wischik. "We are building on over thirty years of research, and the encouraging results from our previous Phase 2 clinical trial in Alzheimer's disease support an approach which targets the abnormal Tau aggregates in the brain."

The studies, which have already starting enrolling in the U.S., aim to confirm the disease-modifying effects seen in the Phase 2 studies in mild to moderate patients over an 18-month timeframe. The first study will involve 833 people with mild to moderate Alzheimer's disease over 12 months.[2] The second study will include 500 people with mild Alzheimer's disease over 18 months.[3]

The study drug, LMTX™, is a second-generation TAI that targets the Tau tangles and their precursors, dissolving them in order to halt their harmful effects on memory.[4]-[6] LMTX™ also works on the early stage Tau aggregates (called 'oligomers') which are precursors to fully-formed tangles and are thought to be particularly toxic.[7]

"Clinicians devoted to Alzheimer's disease have been waiting for a promising agent with disease-modifying properties," said Professor Serge Gauthier of the McGill Centre for Studies in Aging, Quebec, Canada. "The basic science data for this agent, particularly in the tauopathies, looks sound and the interest among investigators and among families is high." Professor Gauthier is a clinical investigator and scientific advisor for TauRx.

The tangles in the brain were first reported by Dr. Alois Alzheimer in 1907,[8] starting the century-long journey to understand the pathology leading to their formation, their role in dementia, and, ultimately, how to stop their spread through the brain.

Professor Lon Schneider, MD, of the Keck School of Medicine at the University of Southern California, a scientific advisor for TauRx, said: "Successfully targeting Tau may be an important approach towards slowing and ideally halting the neuro-degeneration that is characteristic of Alzheimer's disease or frontotemporal dementia. Clinicians need these Phase 3 studies to produce clear evidence that such an approach could lead to improved patient outcomes."

Countries in which the Phase 3 clinical trials will be conducted include Australia, Belgium, Canada, Finland, France, Germany, Italy, Russia, Spain, Netherlands, Singapore, Malaysia, Taiwan, U.S., and U.K.  Patients and caregivers are invited to sign up for study updates at http://www.AlzheimersStudies.com, as the clinical trials are initiated in the countries selected.


About Alzheimer's Disease and Tau Tangles:

Alzheimer's disease is one of the most important health challenges worldwide, and the most-common type of dementia. According to the Geneva-based World Health Organization, global dementia cases are expected to double within 20 years to an estimated 65.7 million people [more than the entire population of France currently at 63 million people].[9] In very early, asymptomatic Alzheimer's, pre-tangle Tau aggregates (oligomers) and Tau protein tangles are already present in the same regions of the brain where neuronal degeneration and loss of neuronal cells eventually occur.[10],[11] These changes first appear 20 - 30 years before the disease becomes clinically evident. With time, Tau tangles spread from the entorhinal cortex (responsible for learning, memory, thinking and planning) through the hippocampus to the neocortex (affecting the ability to communicate, recognize family and loved ones and to care for oneself), resulting in neuronal dysfunction and worsening of clinical symptoms.[11] The spread is now thought to be due to a prion-like process whereby the oligomers act as 'infectious particles' which are able to propagate the abnormal aggregation of Tau protein from one neurone to the next.[12] These oligomers recruit normal Tau to produce yet more infectious oligomers which spread neuronal destruction throughout the brain.  

About TauRx Therapeutics:

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on an entirely new approach which targets aggregates of abnormal fibres of Tau protein that form inside nerve cells in the brain, giving rise to Tangles. The TauRx team have since discovered that LMTX™ could also have beneficial effects in several other neurodegenerative diseases associated with Tau pathology, as well as other protein aggregation disorders including Parkinson's, Huntington's and Frontotemporal Dementia [FTD-Pick's Disease], Progressive Supranuclear Palsy and Cortico-Basal Degeneration. While TauRx corporate headquarters are in Singapore, its primary research facilities are in Aberdeen, Scotland.


References:

  1. Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor (TAI) therapy with rember[TM] arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's and Dementia 2008;4:T167. Abstract available at: http://www.alzheimersanddementia.com/article/S1552-5260(08)00598-0/fulltext. Accessed October 2012.
  2. ClinicalTrials.gov. Safety and efficacy study evaluating TRx0237 in subjects with mild to moderate Alzheimer's disease. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01689246. Accessed October 2012.
  3. ClinicalTrials.gov. Safety and efficacy study evaluating TRx0237 in subjects with mild Alzheimer's disease. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01689233. Accessed October 2012.
  4. Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93:11213-11218. Full article available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC38310/. Accessed October 2012.
  5. Wischik CM, Lai RYK, Harrington CR. Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development. In: Brain MicrotubuleAssociated Proteins: Modifications in Disease, eds. Avila J, Brandt R, Kosik KS. (1997) pp. 185-241. Amsterdam: Harwood Academic Publishers.
  6. Wischik CM, Wischik DJ, Storey JMD, Harrington CR. Rationale for tau-aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In: Emerging Drugs and Targets for Alzheimer's Disease. Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism, ed. Martinez A. (2010) pp. 210-232. Cambridge: RSC Publishing.
  7. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005;280:7614-7623. Full article available at: http://www.jbc.org/content/280/9/7614.long. Accessed October 2012.
  8. Alzheimer A. On a peculiar disease of the cerebral cortex. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Geritlich Medicin 1907;64:146-148.
  9. World Health Organization News Release. Dementia cases set to triple by 2050 but still largely ignored. Available at: http://www.who.int/mediacentre/news/releases/2012/dementia_20120411/en/index.html. Accessed October 2012.
  10. Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, Gertz HJ, Xuereb JH, Hills R, et al. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 2000;157:623-636. Full article available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850134/. Accessed October 2012.
  11. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259. Abstract available at: http://www.ncbi.nlm.nih.gov/pubmed/1759558. Accessed October 2012.
  12. Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012; 149:968-977. Full article available at: http://www.sciencedirect.com/science/article/pii/S0092867412005818. Accessed October 2012.


SOURCE TauRx Therapeutics Ltd

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understa...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
Industry after industry is under siege as companies embrace digital transformation (DX) to disrupt existing business models and disintermediate their competitor’s customer relationships. But what do we mean by “Digital Transformation”? The coupling of granular, real-time data (e.g., smartphones, connected devices, smart appliances, wearables, mobile commerce, video surveillance) with modern technologies (e.g., cloud native apps, big data architectures, hyper-converged technologies, artificial in...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
CloudEXPO has been the M&A capital for Cloud companies for more than a decade with memorable acquisition news stories which came out of CloudEXPO expo floor. DevOpsSUMMIT New York faculty member Greg Bledsoe shared his views on IBM's Red Hat acquisition live from NASDAQ floor. Acquisition news was announced during CloudEXPO New York which took place November 12-13, 2019 in New York City.
OpsRamp is an enterprise IT operation platform provided by US-based OpsRamp, Inc. It provides SaaS services through support for increasingly complex cloud and hybrid computing environments from system operation to service management. The OpsRamp platform is a SaaS-based, multi-tenant solution that enables enterprise IT organizations and cloud service providers like JBS the flexibility and control they need to manage and monitor today's hybrid, multi-cloud infrastructure, applications, and wor...
The Master of Science in Artificial Intelligence (MSAI) provides a comprehensive framework of theory and practice in the emerging field of AI. The program delivers the foundational knowledge needed to explore both key contextual areas and complex technical applications of AI systems. Curriculum incorporates elements of data science, robotics, and machine learning-enabling you to pursue a holistic and interdisciplinary course of study while preparing for a position in AI research, operations, ...
Codete accelerates their clients growth through technological expertise and experience. Codite team works with organizations to meet the challenges that digitalization presents. Their clients include digital start-ups as well as established enterprises in the IT industry. To stay competitive in a highly innovative IT industry, strong R&D departments and bold spin-off initiatives is a must. Codete Data Science and Software Architects teams help corporate clients to stay up to date with the mod...
Tapping into blockchain revolution early enough translates into a substantial business competitiveness advantage. Codete comprehensively develops custom, blockchain-based business solutions, founded on the most advanced cryptographic innovations, and striking a balance point between complexity of the technologies used in quickly-changing stack building, business impact, and cost-effectiveness. Codete researches and provides business consultancy in the field of single most thrilling innovative te...
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
CloudEXPO has been the M&A capital for Cloud companies for more than a decade with memorable acquisition news stories which came out of CloudEXPO expo floor. DevOpsSUMMIT New York faculty member Greg Bledsoe shared his views on IBM's Red Hat acquisition live from NASDAQ floor. Acquisition news was announced during CloudEXPO New York which took place November 12-13, 2019 in New York City. Our Silicon Valley 2019 schedule will showcase 200 keynotes, sessions, general sessions, power panels, and...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...
ShieldX's CEO and Founder, Ratinder Ahuja, believes that traditional security solutions are not designed to be effective in the cloud. The role of Data Loss Prevention must evolve in order to combat the challenges of changing infrastructure associated with modernized cloud environments. Ratinder will call out the notion that security processes and controls must be equally dynamic and able to adapt for the cloud. Utilizing four key factors of automation, enterprises can remediate issues and impro...
Intel is an American multinational corporation and technology company headquartered in Santa Clara, California, in the Silicon Valley. It is the world's second largest and second highest valued semiconductor chip maker based on revenue after being overtaken by Samsung, and is the inventor of the x86 series of microprocessors, the processors found in most personal computers (PCs). Intel supplies processors for computer system manufacturers such as Apple, Lenovo, HP, and Dell. Intel also manufactu...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential. DevOpsSUMMIT at CloudEXPO expands the DevOps community, enable a wide sharing of knowledge, and educate delegates and technology providers alike.